Clinical Trials Logo

Clinical Trial Summary

It is well established in the scientific literature that people with schizophrenia smoke tobacco cigarettes at rates up to three times that of the general population, relapse more frequently, and die an average of 25 years earlier from cigarette smoking and other life-style attributable illnesses. Electronic cigarettes (e-cigarettes) are becoming increasingly popular with smokers worldwide and new research suggests that e-cigarettes are appealing to smokers with schizophrenia. There is a paucity of research focused on the experience of smokers with schizophrenia who decide to try an e-cigarette. A well-designed prospective-observational study is needed to learn more about the influence of e-cigarette use on cigarette smoking behavior and mental and physical health among smokers with schizophrenia. In response, the investigators have designed a study titled, Role of an electronic cigarette on smoking displacement in smokers with schizophrenia: A prospective 3-month pilot study (SchizEcig).


Clinical Trial Description

This is a prospective 3 month pilot study to observe cigarette use behavior among people with a schizophrenia spectrum disorder diagnosis who smoke conventional tobacco cigarettes, do not intend to reduce or quit smoking, and are invited to use an e-cigarette. The investigators are interested to know if e-cigarette use is associated with cigarette smoking displacement. Displacement is defined as switching from conventional tobacco cigarettes to e-cigarettes. The investigators will also monitor for physical and mental health, including blood pressure, weight, and scores from the Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS) as well as any reported adverse events participants' feel are attributed to e-cigarette use and participants' perceptions of the sensory experience associated with e-cigarette use. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03075202
Study type Observational
Source Weill Medical College of Cornell University
Contact
Status Completed
Phase
Start date March 3, 2017
Completion date December 24, 2018

See also
  Status Clinical Trial Phase
Completed NCT05083377 - Clozapine Use Pattern in the Province of Seville
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Recruiting NCT06134661 - Accelerated rTMS for Psychomotor Slowing N/A
Completed NCT01433094 - Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia N/A
Terminated NCT05526833 - An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study N/A
Recruiting NCT05982158 - Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices N/A
Active, not recruiting NCT06175559 - Embedded Narrative in Interactive Game Design for Improving Medication Adherence of Schizophrenia N/A
Active, not recruiting NCT05673941 - "InMotion" - Physical Training With Creative Movement as an Intervention for Adults With Schizophrenia N/A
Recruiting NCT02916810 - TMS for Symptom Reduction in Schizophrenia N/A
Recruiting NCT05958875 - The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Phase 4
Recruiting NCT03525054 - Semantic and Syntactic Computerized Analysis of Free Speech
Recruiting NCT05389345 - tDCS and Executive Function Training for Schizophrenia N/A
Completed NCT05601050 - Linguistic Predictors of Outcomes in Psychosis
Completed NCT03921450 - Overcoming Psychomotor Slowing in Psychosis (OCoPS-P) N/A
Completed NCT06231407 - Increasing Medication Check Participation Through Applying CT-r N/A
Recruiting NCT04478838 - "Extended" (Alternate Day) Antipsychotic Dosing Phase 4
Completed NCT04366401 - Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic Disorders N/A
Completed NCT04612777 - A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses N/A
Not yet recruiting NCT06191965 - MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction Phase 2/Phase 3
Recruiting NCT04321759 - Comparative Effectiveness of CET vs. SST in SMI (Serious Mental Illness) N/A